← Back to headlines
Morgan Stanley Raises Vertex Pharmaceuticals Price Target to $612
Morgan Stanley has increased its price target for Vertex Pharmaceuticals to $612 from $596, indicating a positive outlook for the company's stock.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
